Biocon Biologics refinances $1.1 bn long-term debt via bonds, new facility 0 03.10.2024 08:05 Business Standard Biocon Biologics Global, a wholly-owned subsidiary of BBL, will issue the bonds, which will be secured by a robust collateral package Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
